PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands.
Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):972-8. doi: 10.1002/pds.2187. Epub 2011 Jul 11.
To determine the thromboprophylactic treatment pattern and occurrence of venous thromboembolism (VTE), major bleeding, and wound infections in patients undergoing total knee replacement (TKR) or total hip replacement (THR).
From the PHARMO database, all patients ≥ 18 years hospitalized for TKR or THR between January 2003 and September 2008 were selected. Patients with pharmacy data up to 3 months after hospitalization were included in the study cohort. Duration and type of thromboprophylaxis were assessed. VTE, major bleeding, and wound infections were identified by hospitalizations. Regarding VTE, timing of event in relation to thromboprophylaxis was determined.
The study population included 2930 patients with TKR, 5332 patients with THR without hip fracture, and 289 patients with THR and hip fracture. Mean duration of thromboprophylaxis was about 30 (± 20) days for all procedures, with low-molecular-weight heparin being the most frequently used drug. During 3 months of follow-up, 1% to 2% of patients were hospitalized for an event. The most observed event was wound infection (58%), followed by major bleeding (29%), and VTE (13%). For wound infection and major bleeding, median time after surgery was about 19 days. Median time between surgery and VTE was 24 days for TKR and 60 days for THR. Eighteen of 23 VTE occurred during thromboprophylaxis.
Although patients are often treated for fewer days than recommended, thromboprophylaxis after TKR and THR in the Netherlands is adequate. Only 5 of 23 VTE hospitalizations occurred off-treatment and might have been prevented. Furthermore, fewer than 1% of patients were hospitalized for bleeding.
确定接受全膝关节置换术(TKR)或全髋关节置换术(THR)的患者的血栓预防治疗模式和静脉血栓栓塞症(VTE)、大出血和伤口感染的发生情况。
从 PHARMO 数据库中,选择 2003 年 1 月至 2008 年 9 月期间因 TKR 或 THR 住院的所有年龄≥18 岁的患者。将在住院后 3 个月内有药房数据的患者纳入研究队列。评估血栓预防的持续时间和类型。通过住院确定 VTE、大出血和伤口感染。关于 VTE,确定事件发生与血栓预防的时间关系。
研究人群包括 2930 例 TKR 患者、5332 例无髋部骨折的 THR 患者和 289 例髋部骨折的 THR 患者。所有手术的平均血栓预防持续时间约为 30(±20)天,低分子肝素是最常用的药物。在 3 个月的随访期间,1%至 2%的患者因事件住院。最常见的事件是伤口感染(58%),其次是大出血(29%)和 VTE(13%)。对于伤口感染和大出血,术后中位数时间约为 19 天。TKR 和 THR 后 VTE 的中位数时间分别为 24 天和 60 天。23 例 VTE 中有 18 例发生在治疗期间。
尽管患者的治疗时间往往短于推荐时间,但荷兰 TKR 和 THR 后的血栓预防是充分的。只有 5 例 VTE 住院发生在停药期间,可能可以预防。此外,不到 1%的患者因出血住院。